NEW YORK (Standard&Poor's) Nov. 20, 2013--Standard&Poor's Ratings Services said today that it has reviewed its ratings on Valeant Pharmaceuticals International Inc., which it labeled as "under criteria observation" (UCO) after the publishing of its revised corporate criteria on Nov. 19. Standard&Poor's expedited the review of its ratings on Valeant Pharmaceuticals International Inc. because the company recently issued debt (see "How Standard&Poor?s Plans To Finalize--And Apply--Its Corporate Ratings Criteria," published Nov. 13, 2013). With our criteria review of Valeant Pharmaceuticals International Inc. complete, we have confirmed that our ratings on this issuer are unaffected by the criteria changes.
